

# To determine the kidney function in patients before and after enhanced external counterpulsation treatment

<b>Submission date</b> 25/10/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 17/11/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 23/07/2014	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Prajej Ruangkanhasetr

### Contact details

Assistant Professor, Division of Nephrology  
Department of Medicine  
Phramongkutklao Hospital (Royal Thai Army Hospital)  
315 Rajavithi Road  
Rajathevi  
Bangkok  
Thailand  
10240  
+66 (0)2 644 4676  
prajej@gmail.com

## Additional identifiers

## Study information

Scientific Title

To determine the kidney function by using serum cystatin C in patients before and after enhanced external counterpulsation treatment

### **Study objectives**

Enhanced external counterpulsation (EECP) is based on the principle of diastolic augmentation to increase coronary flow while simultaneously decreasing systolic afterload. We proposed that EECP treatment could improve cardiac function, therefore might improve kidney function. The aim of the trial is to see whether EECP treatment can slow the progression of kidney disease in patients with ischemic heart disease and congestive heart failure.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Institutional Review Board of Piyavate Hospital, approved on 25/10/2006 (ref: 006/2006)

### **Study design**

Single-centre observational study

### **Primary study design**

Observational

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Ischaemic heart disease, chronic stable angina, chronic stable heart failure

### **Interventions**

All patients will receive EECP typically involving 35 x 1-h sessions of counterpulsations over a 7-week period.

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome(s)**

Serum cystatin C

All primary and secondary outcome measures will be assessed before and within 1 month, and 5-7 months after completion of EECP treatment of 35 sessions.

### **Key secondary outcome(s)**

1. Calculated glomerular filtration rate (GFR)
2. Serum N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP)
3. Ejection fraction determined by echocardiography

All primary and secondary outcome measures will be assessed before and within 1 month, and 5-7 months after completion of EECp treatment of 35 sessions.

**Completion date**

30/11/2009

## Eligibility

**Key inclusion criteria**

1. Both males and females, age >18 years
2. Patients with refractory angina, chronic stable angina or chronic stable heart failure
3. Willing to participate in the study with informed consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Patient with the diagnosis of congestive heart failure within 1 month prior to study entry
2. Patient with the diagnosis of acute coronary syndrome within 1 month prior to study entry
3. Patient with uncontrolled blood pressure (>180/110 mmHg)
4. Patient with cardiac arrhythmia (e.g. atrial fibrillation or atrial flutter or frequent premature ventricular contractions) that may interfere with triggering of EECp system
5. Patients with severe lower extremity vaso-occlusive disease
6. Patients with end stage renal disease requiring renal replacement therapy

**Date of first enrolment**

01/11/2006

**Date of final enrolment**

30/11/2009

## Locations

**Countries of recruitment**

Thailand

**Study participating centre**  
Assistant Professor, Division of Nephrology  
Bangkok  
Thailand  
10240

## Sponsor information

**Organisation**  
Piyavate Hospital (Thailand)

## Funder(s)

**Funder type**  
Hospital/treatment centre

**Funder Name**  
This is an investigator-initiated study, carried out in collaboration with the following hospitals:

**Funder Name**  
Piyavate Hospital (Thailand)

**Funder Name**  
Ramathibodi Hospital (Thailand)

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	11/09/2013		Yes	No